Delivery Order SPE2DP20D0002-SPE2DP26F0987
Award Date 12/1/25
Potential Completion Date 12/9/25
Potential Value $165K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- The U.S. Department of Defense's Medical Supply Chain awarded a $660,627.72 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. Issued on December 1, 2025, with an ultimate completion date of December 9, 2025, this delivery order represents one of over 150 awards the company has received since 2023 under an indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- The U.S. Department of Defense's Medical Supply Chain, through the Defense Logistics Agency Troop Support Medical, awarded a $330,313.86 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, issued on June 16, 2025, with an ultimate completion date of June 24, 2025, carries no set-aside designation and will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as...
- On December 1, 2025, the Defense Logistics Agency Troop Support Medical awarded a $330,313.86 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. The contract, with an ultimate completion date of December 9, 2025, represents a delivery order issued under an indefinite delivery contract vehicle and will be performed at Teva's facility in Parsippany, New Jersey. This award carries no set-aside designation and is structured as a firm...
- The U.S. Department of Defense, through the Defense Logistics Agency Troop Support Medical, awarded a delivery order valued at $330,313.86 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, awarded on July 14, 2025, with a completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed-price delivery order valued at $330,313.86 for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. The contract, issued without set-aside designation by the Defense Logistics Agency Troop Support Medical on December 1, 2025, will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents one of over 150 similar awards issued to Teva since 2023, positioning the company as a...